Evidence map›Paper›PMID 29269795›Full record

ArticleBone marrow transplantation2018

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.

Surbhi Sidana, Nidhi Tandon, Morie A Gertz, Angela Dispenzieri, Francis K Buadi, Martha Q Lacy, David Dingli, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Light Chain Amyloidosis.Mediterranean journal of hematology and infectious diseases · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Surbhi SidanaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Nidhi TandonDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Morie A GertzDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Angela DispenzieriDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Francis K BuadiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Martha Q LacyDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
David DingliDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Amie L FonderDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Suzanne R HaymanDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Miriam A HobbsDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Wilson I GonsalvesDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Yi Lisa HwaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Prashant KapoorDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Robert A KyleDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Nelson LeungDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID http://orcid.org/0000-0002-5651-1411
Ronald S GoDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
John A LustDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Stephen J RussellDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Steven R ZeldenrustDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
S Vincent RajkumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
William J HoganDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID http://orcid.org/0000-0002-5841-4105
Shaji K KumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. kumar.shaji@mayo.edu.ORCID http://orcid.org/0000-0001-5392-9284
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Use of melphalan in multiple myeloma was observed to have a deleterious effect on stem cell collection in older studies. There is limited data on the impact of melphalan in light chain (AL) amyloidosis, especially in the plerixafor era. We retrospectively evaluated stem cell mobilization in 610 patients with AL amyloidosis, of which 79 had prior exposure to melphalan, 167 to other chemotherapeutics, while 364 had no chemotherapy exposure. Collection of CD34+ stem cells × 10

Indexed as

AgedAlgorithmsAntigens, CD34BenzylaminesCyclamsFemaleHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansImmunoglobulin Light-chain AmyloidosisMaleMelphalanMiddle AgedRetrospective StudiesAntigens, CD34BenzylaminesCyclamsHeterocyclic CompoundsMelphalanplerixafor

Identifiers

PMID29269795
OpenAlexW2772670513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.